Tumor infiltrating lymphocytes (TILs) represent a strong independent predictor of relapse and overall survival in colorectal cancer (CRC). However, it appears that a majority of CRCs, i.e., microsatellite stable (MSS) tumors, are refractory to immune checkpoint blockers. The results of recent comprehensive analyses of genomic data provide possible answers.
No takes yet. Share an insight, caveat, or question.
Angelova et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: